Similarly, another assay method revealed that cotreatment of the cells with TOP and elacridar in a concentration of 5 μM significantly decreased the IC50 of treated cells—by 32-fold in the BCRP-expressing, drug-resistant human ovarian adenocarcinoma IGROV1-derived T8 cell line and by 5-fold in the canine kidney MDCKII-BCRP1 cell line—compared to cells treated with TOP alone [49]. This evidence concerns the gene BCRP1 and ovarian adenocarcinoma.